M&A / Deals Biogen, with $5.6B Apellis buy, builds out immunology offerings pharminent March 31, 2026
M&A / Deals Novartis targets Xolair successor in buyout of startup Excellergy pharminent March 27, 2026
M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war pharminent March 26, 2026
M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug pharminent March 25, 2026
M&A / Deals Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases pharminent March 24, 2026
M&A / Deals Immutrin raises $87M to advance drug for progressive heart disease pharminent March 24, 2026
